Company logo

EBS - Emergent BioSolutions Inc.

NYSE -> Healthcare -> Drug Manufacturers—Specialty & Generic
Gaithersburg, United States
Type: Equity

EBS price evolution
EBS
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $71 $79 $111.7
Short term investments
Net receivables $121.3 $196.3 $233.5 $191
Inventory $322.7 $317.5 $333.4 $328.9
Total current assets $661.4 $654.5 $682.4 $679.5
Long term investments
Property, plant & equipment $290.5 $306.2 $379.4 $382.8
Goodwill & intangible assets $534.1 $550.4 $566.6
Total noncurrent assets $859 $1121.2 $1143.7
Total investments
Total assets $1477.8 $1513.5 $1803.6 $1823.2
Current liabilities
Accounts payable $82.1 $95.9 $100.2 $112.2
Deferred revenue
Short long term debt $415.2 $459.2 $413.7
Total current liabilities $229.9 $619.7 $630.2 $651.3
Long term debt $661.8 $447 $446.7 $446.5
Total noncurrent liabilities $507.5 $509.5 $522.6
Total debt $862.2 $905.9 $860.2
Total liabilities $969.4 $1127.2 $1139.7 $1173.9
Shareholders' equity
Retained earnings -$181.1 -$295.9 -$12.8 -$21.8
Other shareholder equity -$7.3 -$5.5 -$5.5 -$5.7
Total shareholder equity $386.3 $663.9 $649.3
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $111.7 $642.6 $576.3 $621.5
Short term investments
Net receivables $191 $158.4 $274.7 $230.9
Inventory $328.9 $351.8 $350.8 $307
Total current assets $679.5 $1210.7 $1272.1 $1195.9
Long term investments
Property, plant & equipment $382.8 $837 $800.1 $644.1
Goodwill & intangible assets $566.6 $947 $829.5 $929.8
Total noncurrent assets $1143.7 $1955.9 $1686.9 $1687.3
Total investments
Total assets $1823.2 $3166.6 $2959 $2883.2
Current liabilities
Accounts payable $112.2 $103.5 $128.9 $136.1
Deferred revenue
Short long term debt $413.7 $957.3 $31.6 $33.8
Total current liabilities $651.3 $1229.9 $373.8 $384.5
Long term debt $446.5 $448.5 $809.4 $841
Total noncurrent liabilities $522.6 $553.7 $966.2 $1051.7
Total debt $860.2 $1405.8 $841 $874.8
Total liabilities $1173.9 $1783.6 $1340 $1436.2
Shareholders' equity
Retained earnings -$21.8 $734 $957.8 $726.9
Other shareholder equity -$5.7 $3.1 -$16.1 -$25.3
Total shareholder equity $649.3 $1383 $1619 $1447
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $254.7 $300.4 $276.6
Cost of revenue $296.1 $144.6 $185.1
Gross Profit -$41.4 $155.8 $91.5
Operating activities
Research & development $32.7 $15.1 $29.4
Selling, general & administrative $85.9 $84.7 $89.7
Total operating expenses $162.1 $116 $135.3
Operating income -$203.5 $39.8 -$43.8
Income from continuing operations
EBIT -$246.2 $36.4 -$32.8
Income tax expense $13.3 $3.1 -$5
Interest expense $23.6 $24.3 $21.7
Net income
Net income -$283.1 $9 -$49.5
Income (for common shares) -$283.1 $9 -$49.5
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $1049.3 $1120.9 $1792.7 $1555.4
Cost of revenue $705.4 $693.7 $757.5 $524
Gross Profit $343.9 $427.2 $1035.2 $1031.4
Operating activities
Research & development $111.4 $193 $234 $234.5
Selling, general & administrative $368.4 $340.3 $348.4 $303.3
Total operating expenses $1070.3 $599.9 $682.6 $597.6
Operating income -$726.4 -$172.7 $352.6 $433.8
Income from continuing operations
EBIT -$643.3 -$184.4 $348.9 $438.5
Income tax expense $29.3 $2.1 $83.5 $102.1
Interest expense $87.9 $37.3 $34.5 $31.3
Net income
Net income -$760.5 -$223.8 $230.9 $305.1
Income (for common shares) -$760.5 -$223.8 $230.9 $305.1
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$283.1 $9 -$49.5
Operating activities
Depreciation $28.5 $27.9 $29.6
Business acquisitions & disposals
Stock-based compensation $5.5 $5.9 $4
Total cash flows from operations $47.5 -$62.6 $32.1
Investing activities
Capital expenditures -$4.6 -$10.8 -$11.4
Investments
Total cash flows from investing $96.6 -$4.6 -$10.8 -$11.4
Financing activities
Dividends paid
Sale and purchase of stock $0.7 $0.7
Net borrowings -$51.4 $41.1 $4.1
Total cash flows from financing -$190.5 -$50.9 $40.7 $4.7
Effect of exchange rate -$1.5
Change in cash and equivalents $44.7 -$8 -$32.7 $23.9
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$760.5 -$223.8 $230.9 $305.1
Operating activities
Depreciation $125.1 $143.3 $123.8 $114.5
Business acquisitions & disposals $263.9 -$243.7 -$10
Stock-based compensation $23.1 $45.1 $42.4 $51
Total cash flows from operations -$206.3 -$34.1 $321.1 $536
Investing activities
Capital expenditures -$51.6 -$115.8 -$225 -$141
Investments
Total cash flows from investing $212.3 -$381.3 -$225 -$151
Financing activities
Dividends paid
Sale and purchase of stock $10.2 -$77.1 -$90.1 $31.6
Net borrowings -$543.4 $564.2 -$35.9 $54.5
Total cash flows from financing -$535.7 $481.2 -$141 $69.5
Effect of exchange rate -$1.2 $0.5 -$0.3 -$1
Change in cash and equivalents -$530.9 $66.3 -$45.2 $453.5
Fundamentals
Market cap $608.63M
Enterprise value N/A
Shares outstanding 54.10M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.81
Net debt/EBITDA N/A
Current ratio 2.88
Quick ratio 1.47